Literature DB >> 21151716

Serum Serotonin Levels are Associated with Antiviral Therapy Outcomes in Patients with Chronic Hepatitis C.

Jennifer M Loftis1, Benjamin J Morasco, Daniel Menasco, Dietmar Fuchs, Max Strater, Peter Hauser.   

Abstract

The role of serotonin in contributing to viral clearance has not been investigated in patients with chronic hepatitis C (HCV). In this prospective study we collected blood samples from 39 patients prior to and during antiviral therapy. Participants completed mood rating scales to monitor psychiatric symptoms, and serum serotonin and tryptophan levels were measured. Significant differences in serotonin levels were found between patients who achieved sustained viral responses (SVRs) and those who did not. Regression analysis revealed that serotonin was the only variable with a statistically significant relationship with antiviral therapy outcomes, even after controlling for other variables known to be associated with outcomes. Baseline serum serotonin levels, in combination with other variables such as degree of liver fibrosis, may be clinically useful for identifying patients in whom HCV can be cleared by antiviral therapy. Additional clinical predictors that could forecast treatment success are needed so that interventions to improve SVR rates, and reduce side effects, can be developed.

Entities:  

Year:  2010        PMID: 21151716      PMCID: PMC2999909          DOI: 10.2174/1874279301004010132

Source DB:  PubMed          Journal:  Open Infect Dis J


  52 in total

Review 1.  Hepatitis C in African Americans: summary of a workshop.

Authors:  C Howell; L Jeffers; J H Hoofnagle
Journal:  Gastroenterology       Date:  2000-11       Impact factor: 22.682

2.  Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism.

Authors:  Sascha Russo; Ido P Kema; Elizabeth B Haagsma; Jim C Boon; Pax H B Willemse; Johan A den Boer; Elisabeth G E de Vries; Jakob Korf
Journal:  Psychosom Med       Date:  2005 Sep-Oct       Impact factor: 4.312

3.  The effect of hepatic stimulator substance (HSS) on liver regeneration arrest induced by 5-HT2 receptor blockade.

Authors:  Konstantinos N Tzirogiannis; Georgios I Panoutsopoulos; George K Papadimas; Maria D Demonakou; Rosa I Hereti; Georgia A Manta; Kalliopi T Kourentzi; Vasiliki G Kondili; Katerina N Alexandropoulou; Michael G Mykoniatis
Journal:  In Vivo       Date:  2005 Sep-Oct       Impact factor: 2.155

4.  Contribution of serotonin to liver injury following canine small-intestinal ischemia and reperfusion.

Authors:  N Nakamura; N Hamada; R Murata; A Kobayashi; N Ishizaki; A Taira; R Sakata
Journal:  J Surg Res       Date:  2001-07       Impact factor: 2.192

5.  Platelet-derived serotonin mediates liver regeneration.

Authors:  Mickael Lesurtel; Rolf Graf; Boris Aleil; Diego J Walther; Yinghua Tian; Wolfram Jochum; Christian Gachet; Michael Bader; Pierre-Alain Clavien
Journal:  Science       Date:  2006-04-07       Impact factor: 47.728

6.  Oxalic acid stabilizes dopamine, serotonin, and their metabolites in automated liquid chromatography with electrochemical detection.

Authors:  A Kankaanpää; E Meririnne; K Ariniemi; T Seppälä
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-04-05

7.  Induction of DNA synthesis in primary cultures of rat hepatocytes by serotonin: possible involvement of serotonin S2 receptor.

Authors:  S Balasubramanian; C S Paulose
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

8.  Effect of serotonin receptor 2 blockage on liver regeneration after partial hepatectomy in the rat liver.

Authors:  George K Papadimas; Konstantinos N Tzirogiannis; Georgios I Panoutsopoulos; Maria D Demonakou; Spyridon D Skaltsas; Rosa I Hereti; Zeta Papadopoulou-Daifoti; Michael G Mykoniatis
Journal:  Liver Int       Date:  2006-04       Impact factor: 5.828

9.  Aggravation of viral hepatitis by platelet-derived serotonin.

Authors:  Philipp A Lang; Claudio Contaldo; Panco Georgiev; Ashraf Mohammad El-Badry; Mike Recher; Michael Kurrer; Luisa Cervantes-Barragan; Burkhard Ludewig; Thomas Calzascia; Beatrice Bolinger; Doron Merkler; Bernhard Odermatt; Michael Bader; Rolf Graf; Pierre-Alain Clavien; Ahmed N Hegazy; Max Löhning; Nicola L Harris; Pamela S Ohashi; Hans Hengartner; Rolf M Zinkernagel; Karl S Lang
Journal:  Nat Med       Date:  2008-05-30       Impact factor: 53.440

10.  Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C.

Authors:  Robert J Fontana; Ziad Kronfol; Karen L Lindsay; Linas A Bieliauskas; Latha Padmanabhan; Carla Back-Madruga; Anna S F Lok; Anne M Stoddard
Journal:  Am J Gastroenterol       Date:  2008-08-21       Impact factor: 10.864

View more
  3 in total

1.  Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study.

Authors:  Jennifer M Loftis; Alexander L Patterson; Clare J Wilhelm; Henry McNett; Benjamin J Morasco; Marilyn Huckans; Timothy Morgan; Shira Saperstein; Aliya Asghar; Peter Hauser
Journal:  J Psychosom Res       Date:  2012-11-21       Impact factor: 3.006

Review 2.  Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications.

Authors:  Peter Hauser; Shira Kern
Journal:  World J Hepatol       Date:  2015-07-28

3.  Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.

Authors:  Jae-Won Lee; Won Kim; Eun-Kyung Kwon; Yuri Kim; Hyun Mu Shin; Dong-Hyun Kim; Chan-Ki Min; Ji-Yeob Choi; Won-Woo Lee; Myung-Sik Choi; Byeong Gwan Kim; Nam-Hyuk Cho
Journal:  PLoS One       Date:  2017-06-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.